Literature DB >> 54208

Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.

A M Bobrove, Z Fuks, S Strober, H S Kaplan.   

Abstract

Peripheral blood T and B lymphocytes were quantitated in 42 patients with untreated Hodgkin's disease and the results compared with the response to phytohemagglutinin (PHA) stimulation and delayed hypersensitivity skin testing. T lymphocytes were identified by an in vitro cytotoxicity assay employing a specific anti-T-cell serum and by spontaneous rosette formation with sheep erythrocytes (E rosettes). The percentage of T cells in the patients was similar to that of normal subjects as judged by the cytotoxicity assay (65 to 90%). In addition, absolute T-lymphocyte counts were normal in 63% of the patients and were generally reduced only in those with lymphopenia. The percentage of T lymphocytes determined by the E-rosette assay was similar to that determined by the cytotoxicity assay in normal controls, but was significantly lower than that determined by the cytotoxicity assay in the patients. Moreover, the decreased response to PHA stimulation in the patients was directly correlated with the decrease in E-rosette formation. These findings suggest that T lymphocytes in the peripheral blood are not generally diminished in untreated Hodgkin's disease. However, a proportion of these cells exhibits altered surface interactions that may account for some aspects of their impaired immunologic function.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 54208     DOI: 10.1002/1097-0142(197507)36:1<169::aid-cncr2820360115>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease.

Authors:  Z Fuks; S Strober; A M Bobrove; T Sasazuki; A McMichael; H S Kaplan
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

2.  Immune function of successfully treated lymphoma patients.

Authors:  G W King; B Yanes; P E Hurtubise; S P Balcerzak; A F LoBuglio
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

3.  Alterations in T and B lymphocytes in heart transplant patients early and late postoperatively.

Authors:  T H Khalaf; S Strober; G Garrelts; E B Stinson
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

4.  Differences in the formation of normal T lymphocyte colonies by peripheral blood cells from patients with chronic lymphocytic leukemia and Hodgkin's disease.

Authors:  D Douer; L Sachs
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

5.  A morphologic and immunologic surface marker study of 299 cases of non-Hodgkin lymphomas and related leukemias.

Authors:  R J Lukes; C R Taylor; J W Parker; T L Lincoln; P K Pattengale; B H Tindle
Journal:  Am J Pathol       Date:  1978-02       Impact factor: 4.307

6.  Ecotaxis: the principle and its application to the study of Hodgkin's disease.

Authors:  M D Sousa; M Yang; E Lopes-Corrales; C Tan; J A Hansen; B Dupont; R A Good
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

7.  Pathophysiological aspects of Hodgkin's disease.

Authors:  D Huhn
Journal:  Klin Wochenschr       Date:  1979-05-16

8.  Morphological changes in the lymphoid organs induced by diphenylhydantoin sodium (DPH).

Authors:  I G Lorand; W A Hadler; L S Prigenzi
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-11-22

9.  Lymphocyte counts and functions in arterial and venous splenic blood of patients with Hodgkin's disease. Evidence for elimination of spontaneously DNA synthesizing cells in the spleen.

Authors:  M Björkholm; G Holm; J Askergren; H Mellstedt
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

10.  Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.

Authors:  S Gupta; G Fernandes
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.